Related Experiment Videos
Focused dengue vaccine development: outwitting nature's design
Stephan T Kudlacek1, Stefan W Metz2
1Department of Biochemistry and Biophysics, University of North Carolina, 125 Mason Farm Road, 6230E Marisco Hall, Chapel Hill, NC 27599, USA.
Pathogens and Disease
|February 7, 2019
Summary
Developing a Dengue virus (DENV) vaccine is difficult due to four serotypes. This review explores enhancing envelope protein (E) based subunit vaccines to improve immunogenicity and efficacy against all DENV serotypes.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Dengue virus (DENV) poses a significant global health threat, with four serotypes causing widespread infections and severe hemorrhagic conditions.
- Current vaccine development faces challenges in achieving simultaneous immunity against all four DENV serotypes, as prior immunity can enhance subsequent infections.
Purpose of the Study:
- To review the limitations of current recombinant envelope protein (E)-based Dengue virus vaccine candidates.
- To discuss strategies for improving the immunogenicity and efficacy of E-based subunit antigens for a tetravalent DENV vaccine.
Main Methods:
- Literature review of existing Dengue virus vaccine research.
- Analysis of challenges associated with recombinant E-protein based vaccine development.
- Exploration of potential solutions to enhance antigen immunogenicity.
Main Results:
- Live-virus vaccine approaches have limitations in inducing protective immunity against all four DENV serotypes.
- Recombinant E-based subunit vaccines show promise but require further optimization.
- Existing E-based antigens need enhancement to be effective vaccine candidates.
Conclusions:
- Recombinant E-based Dengue virus antigens require further development to overcome limitations in immunogenicity.
- Strategies to enhance E-protein subunit antigens are crucial for developing effective tetravalent DENV vaccines.
- Addressing these challenges is key to advancing Dengue virus vaccine efficacy.